While I'm a bit loathe to speculate on short-term share price movements, I suspect the strong performance (not just overnight, but in preceding weeks) will be due to a combination of two things:
1.) Increasing industry anecdotes about how Resmed's recently-released AirSolutions platform, in conjunction with U-Sleep patient management system, is killing it in the market place, and .
2) ResMed recently presented new data on sleep-disordered breathing in patients with Chronic Heart Failure at the American College of Cardiology 64th Annual Meeting:
SAN DIEGO, March 12, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced data from two studies about sleep-disordered breathing (SDB) in chronic heart failure will be presented at the 64th Annual Scientific Sessions of the American College of Cardiology, from March 14th through 16th.
"The data we are presenting are important because they point toward a connection between breathing disorders in sleep, like sleep apnea, and chronic heart failure," said ResMed Chief Medical Officer, Glenn Richards, M.D. "We look forward to learning the results of our landmark clinical study called SERVE-HF, that examines whether addressing sleep-disordered breathing in people with chronic heart failure improves survival."
Presenting two studies on sleep-disordered breathing in patients with chronic heart failure
Final data from nearly 7,000 patients in a German registry of more than 10,000 patients with stable chronic heart failure showed that SDB was present in nearly one out of two people (46 percent). Prevalence of SDB increased rapidly with age. Other risk factors include male gender, more severe heart failure, atrial fibrillation and increased weight.
This data will be presented in a poster session by Olaf Oldenburg, Senior Cardiologist in the Department of Cardiology at the Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany on Monday, March 16th from 9:45-10:30 a.m. (Session 1252, Poster 212; Prevalence and Predictors of Sleep-Disordered Breathing in Patients with Stable Chronic Heart Failure: Final data of the SchlaHF Registry; Poster Hall B1)
Data from an American study suggest that treatment of SDB may reduce hospital admission rates in patients with chronic heart failure. Patients compliant with positive airway pressure (PAP) therapy had significantly reduced hospital visits in the 6 months after starting therapy compared to the 6 months before therapy. A comparable group who were not compliant with PAP therapy had no change in frequency of hospital visits.
This data will be presented in a poster session by Dr. Sunil Sharma, Associate Professor in the Department of Medicine at Thomas Jefferson University on Saturday, March 14th from 3:45-4:30 p.m. (Session 1145, Poster 192; Treatment Of Sleep Disordered Breathing In Patients Admitted For Decompensated Heart Failure Reduces 6 Months Hospital Visits, Poster Hall B1)
About Sleep-Disordered Breathing
Sleep-disordered breathing encompasses a spectrum of breathing problems during sleep. The two most common types of sleep apnea, a condition that results in repetitive pauses in breathing during sleep, are obstructive sleep apnea and central sleep apnea. In either situation, lack of oxygen causes the person to wake up to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour.
Sleep-disordered breathing is found more commonly in patients with heart failure than it is in the general population, and people with heart failure often report poor sleep as a symptom.
About SERVE-HF SERVE-HF is a large randomized controlled trial that will assess for the first time whether treatment of predominantly central sleep apnea, with ResMed's Minute Ventilation-targeted Adaptive Servo-Ventilation (MV-ASV) therapy can reduce mortality and morbidity in patients with chronic heart failure who are receiving optimized medical therapy
RMD Price at posting:
$9.23 Sentiment: Buy Disclosure: Held
(20min delay)